Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?

Leow, 2015, Perioperative therapy for muscle invasive bladder cancer, Hematol Oncol Clin North Am, 29, 301, 10.1016/j.hoc.2014.11.002 Reardon, 2015, Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides, Eur Urol, 67, 165, 10.1016/j.eururo.2014.01.009 Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148 Culp, 2014, Refining patient selection for neoadjuvant chemotherapy before radical cystectomy, J Urol, 191, 40, 10.1016/j.juro.2013.07.061 Canter, 2011, Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy, BJU Int, 107, 58, 10.1111/j.1464-410X.2010.09442.x Moschini, 2017, Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy, Clin Genitourin Cancer, 15, e267, 10.1016/j.clgc.2016.07.014 Warrick, 2017, Clinical significance of histologic variants of bladder cancer, J Natl Compr Canc Netw, 15, 1268, 10.6004/jnccn.2017.7027 Siefker-Radtke, 2004, Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience, J Urol, 172, 481, 10.1097/01.ju.0000132413.85866.fc Vetterlein, 2017, Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology, Cancer, 123, 4346, 10.1002/cncr.30907 Galsky, 2016, Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer, J Clin Oncol, 34, 825, 10.1200/JCO.2015.64.1076 Seisen, 2018, Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy, JAMA Oncol, 4, 225, 10.1001/jamaoncol.2017.2374 Svatek, 2010, The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder, Clin Cancer Res, 16, 4461, 10.1158/1078-0432.CCR-10-0457 Bellmunt, 2013, Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy, Curr Opin Urol, 23, 466, 10.1097/MOU.0b013e328363de67 Van Allen, 2014, Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma, Cancer Discov, 4, 1140, 10.1158/2159-8290.CD-14-0623 Liu, 2016, Clinical validation of chemotherapy response biomarker ercc2 in muscle-invasive urothelial bladder carcinoma, JAMA Oncol, 2, 1094, 10.1001/jamaoncol.2016.1056 Bellmunt, 2015, Precision and predictive medicine in urothelial cancer: are we making progress?, Eur Urol, 68, 547, 10.1016/j.eururo.2015.04.025 Robertson, 2018, Comprehensive molecular characterization of muscle-invasive bladder cancer, Cell, 174, 1033, 10.1016/j.cell.2018.07.036 Rodriguez-Vida, 2018, The Cancer Genome Atlas project in bladder cancer, Cancer Treat Res, 175, 259, 10.1007/978-3-319-93339-9_12 Seiler, 2017, Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy, Eur Urol, 72, 544, 10.1016/j.eururo.2017.03.030 Choi, 2014, Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy, Cancer Cell, 25, 152, 10.1016/j.ccr.2014.01.009 Sonpavde, 2009, Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy, Cancer, 115, 4104, 10.1002/cncr.24466 Plimack, 2015, Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer, Eur Urol, 68, 959, 10.1016/j.eururo.2015.07.009 McConkey, 2016, Eur Urol, 69, 855, 10.1016/j.eururo.2015.08.034 Griffiths, 2011, International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial, J Clin Oncol, 29, 2171, 10.1200/JCO.2010.32.3139 Lee, 2007, A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery, PNAS, 104, 13086, 10.1073/pnas.0610292104 Southwest Oncology Group. Co-expression extrapolation (COXEN) program to predict chemotherapy response in patients with bladder cancer (COXEN). NCT02177695 (SWOG1314). https://clinicaltrials.gov/ct2/show/NCT02177695. Liu, 2017, Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer, Nat Commun, 8, 2193, 10.1038/s41467-017-02320-7 Groenendijk, 2016, ERBB2 Mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy, Eur Urol, 69, 384, 10.1016/j.eururo.2015.01.014 Groenendijk, 2015, Eur Urol, 68, 333, 10.1016/j.eururo.2015.02.043 Teo, 2017, DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma, Clin Cancer Res, 23, 3610, 10.1158/1078-0432.CCR-16-2520 Alliance for Clinical Trials in Oncology. Gemcitabine hydrochloride and cisplatin in treating participants with invasive bladder urothelial cancer. NCT03609216. https://clinicaltrials.gov/ct2/show/NCT03609216. Fox Chase Cancer Center. Risk adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC. https://clinicaltrials.gov/ct2/show/NCT02710734. Martini, 2017, The use of neoadjuvant chemotherapy in patients with urothelial carcinoma of the bladder: current practice among clinicians, Clin Genitourin Cancer, 15, 356, 10.1016/j.clgc.2016.09.003